These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Le H; Zeng F; Xu L; Liu X; Huang Y Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862 [TBL] [Abstract][Full Text] [Related]
4. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. Chen YC; Hsu HS; Chen YW; Tsai TH; How CK; Wang CY; Hung SC; Chang YL; Tsai ML; Lee YY; Ku HH; Chiou SH PLoS One; 2008 Jul; 3(7):e2637. PubMed ID: 18612434 [TBL] [Abstract][Full Text] [Related]
5. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919 [TBL] [Abstract][Full Text] [Related]
6. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547 [TBL] [Abstract][Full Text] [Related]
7. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130 [TBL] [Abstract][Full Text] [Related]
8. Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line. Zhao C; Setrerrahmane S; Xu H Oncol Rep; 2015 Oct; 34(4):2126-32. PubMed ID: 26239272 [TBL] [Abstract][Full Text] [Related]
9. miR‑181b‑5p mediates TGF‑β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells. Li X; Han J; Zhu H; Peng L; Chen Z Int J Oncol; 2017 Jul; 51(1):158-168. PubMed ID: 28534939 [TBL] [Abstract][Full Text] [Related]
10. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related]
11. IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer. Wu Z; He D; Zhao S; Wang H Mol Cell Biochem; 2019 May; 455(1-2):195-206. PubMed ID: 30564960 [TBL] [Abstract][Full Text] [Related]
12. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/β-catenin-FoxM1-Twist signaling. Su J; Wu S; Wu H; Li L; Guo T Mol Carcinog; 2016 Dec; 55(12):1962-1973. PubMed ID: 26621583 [TBL] [Abstract][Full Text] [Related]
13. Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Schaal CM; Bora-Singhal N; Kumar DM; Chellappan SP Mol Cancer; 2018 Oct; 17(1):149. PubMed ID: 30322398 [TBL] [Abstract][Full Text] [Related]
14. Calcium channel α2δ1 subunit is a functional marker and therapeutic target for tumor-initiating cells in non-small cell lung cancer. Ma Y; Yang X; Zhao W; Yang Y; Zhang Z Cell Death Dis; 2021 Mar; 12(3):257. PubMed ID: 33707423 [TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma. Hao C; Liu G; Tian G Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411 [TBL] [Abstract][Full Text] [Related]
16. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling. Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247 [TBL] [Abstract][Full Text] [Related]
17. Role for ERK1/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis. Xiao GY; Mohanakrishnan A; Schmid SL Proc Natl Acad Sci U S A; 2018 Oct; 115(41):E9570-E9579. PubMed ID: 30249660 [TBL] [Abstract][Full Text] [Related]
18. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer. Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256 [TBL] [Abstract][Full Text] [Related]
19. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Li F; Zeng H; Ying K Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756 [TBL] [Abstract][Full Text] [Related]
20. CD44+ and CD133+ Non-Small Cell Lung Cancer Cells Exhibit DNA Damage Response Pathways and Dormant Polyploid Giant Cancer Cell Enrichment Relating to Their p53 Status. Pustovalova M; Blokhina T; Alhaddad L; Chigasova A; Chuprov-Netochin R; Veviorskiy A; Filkov G; Osipov AN; Leonov S Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]